Skip to main content
. 2021 Oct 18;12(11):1733–1738. doi: 10.1021/acsmedchemlett.1c00368

Figure 2.

Figure 2

Chemical structures of novel CDK4/6 PROTACs that were specifically designed to cotarget neosubstrates such as IKZF3 or to influence the durability of the PROTAC effect. MM.1S cells were treated with compounds at the indicated concentrations for 16 h. Pomalidomide (POM) and the VHL-based CDK4/6 degrader CST651 were included as controls. Representative Western blot of at least three independent repeats.